Filter by
Filter by
Hypofractionated proton therapy for non-small cell lung cancer: Ready for prime time? A systematic review and meta-analysis.
This systematic review evaluated eight studies and 401 patients with early stage NSCLC treated with hypofractionated PBT to a median total dose of 63 Gy(RBE)...
Cardiopulmonary Toxicity Following Intensity-Modulated Proton Therapy (IMPT) Versus Intensity-Modulated Radiation Therapy (IMRT) for Stage III Non-Small Cell Lung Cancer.
163 consecutively treated patients with biopsy-proven, stage III NSCLC who received IMPT (n = 35, 21%) or IMRT (n = 128, 79%) were analyzed in this study...
Lung treatment with pencil beam scanner at the Texas Center of Proton Therapy
The Texas Center for Proton Therapy brings an advanced cancer treatment to North Texas that offers more hope to cancer patients. The 63,000-square-foot center...
Clinical experience from the first compact IMPT Proton Therapy Center: the advantages of treating in an open gantry environment
The Willis-Knighton Health System, headquartered in Shreveport, Louisiana, is a not-for-profit community healthcare corporation with four general acute care...
Emerging Proton Therapy Indication: Lung Cancer
Joe Chang gives a presentation on using proton therapy for lung cancer. He talks about the advantages over photons, the improvements of IMPT compared to PSPT...